High Expression Level of Preoperative Serum Uroplakin III is Associated with Biologically Aggressive Bladder Cancer |
Tsumura, Hideyasu
(Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University)
Matsumoto, Kazumasa (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) Ikeda, Masaomi (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) Yanagita, Kengo (Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University) Hirano, Shuhei (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) Hagiwara, Masahiro (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) Nagashio, Ryo (Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University) Fujita, Tetsuo (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) Sato, Yuichi (Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University) Iwamura, Masatsugu (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) |
1 | Bringuier PP, Umbas R, Schaafsma HE, et al (1993). Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res, 53, 3241-5. |
2 | El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al (2009). Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol, 19, 1575-81. DOI |
3 | Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-403. DOI |
4 | Griffiths G, Hall R, Sylvester R, et al (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol, 29, 2171-7. DOI |
5 | Huang HY, Shariat SF, Sun TT, et al (2007). Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol, 38, 1703-13. DOI |
6 | Ikeda M, Matsumoto K, Nishi M, et al (2014). Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. Asian Pac J Cancer Prev, 15, 6519-24. DOI |
7 | Kobayashi M, Matsumoto T, Ryuge S, et al (2012). CAXII Is a sero-diagnostic marker for lung cancer. PLoS One, 7, 33952. DOI |
8 | Li SM, Zhang ZT, Chan S, et al (1999). Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol, 162, 931-5. DOI |
9 | Lu JJ, Kakehi Y, Takahashi T, et al (2000). Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res, 6, 3166-71. |
10 | Matsumoto K, Satoh T, Irie A, et al (2008). Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology, 72, 444-9. DOI |
11 | Matsumoto K, Shariat SF, Casella R, et al (2003). Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol, 170, 2248-52. DOI |
12 | Otunctemur A, Koklu I, Ozbek E, et al (2014). Are bladder neoplasms more aggresive in patients with a smoking-related second malignancy? Asian Pac J Cancer Prev, 15, 4025-8. DOI ScienceOn |
13 | Schwaibold HE, Sivalingam S, May F, Hartung R (2006). The value of a second transurethral resection for T1 bladder cancer. BJU Int, 97, 1199-201. DOI |
14 | Takeuchi M, Sasaki S, Ito M, et al (2009). Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology, 251, 112-21. DOI |
15 | Wang HF and Wang JS (2012). Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer. Asian Pac J Cancer Prev, 13, 1723-6. DOI |
16 | Wu XR, Lin JH, Walz T, et al (1994). Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem, 269, 13716-24. |
17 | Xu X, Sun TT, Gupta PK, et al (2001). Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer, 93, 216-21. DOI |
![]() |